Cipla has over 8 decades of caring for life!
Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
Founded with the aim of self-sufficiency for India in pharmaceutical medicines, The Chemical Industrial and Pharmaceutical Laboratories [CIPLA] registers as a Public Limited Company on Aug 17, 1935
1935 - 1960
Esteemed dignitaries visit CIPLA - Sardar Vallabhbhai Patel, Sushila Nayyar, Shanti Swarup Bhatnagar, Ramaswamy Mudaliar, Amrit Kaur, Gulzarilal Nanda, Morarji Desai, Sir C.V. Raman, Crown Prince Fazl of Saudi Arabia, Rafi Ahmed Kidwai, Mohd. Asaf Ali and Maulana Azad
Mahatma Gandhi visits CIPLA, inspiring the Founder Dr. K.A. Hamied to produce vital and life-saving medicines for India
Cipla steps up to the war-efforts, delivers medicines to Rangoon
CIPLA celebrates India attaining Independence with flag hoisting ceremony at Mumbai Central Headquarters
CIPLA's advertisement features in the 1948 edition of the MARG journal
Foundation stone is laid for Cipla Research & Development block at Mumbai Central
CIPLA exhibits at the All India Medical Conference
CIPLA cricket team wins the E-Merck shield
CIPLA commercialises the technology to extract diosgenin from Dioscorea tubers, for the first time in India
Construction of new laboratories and manufacturing plants commences at Vikhroli.
Dr. Yusuf Khwaja Hamied formally joins CIPLA as a Research and Development Officer (May 15, 1961).
CIPLA's turnover crosses the 1 crore mark.
The Founder and Chairman of CIPLA, Dr. K.A. Hamied, passes away in Tehran. (Jun 23, 1972)
CIPLA lobbies with a handful of committed people to change the existing Patent Law of 1911. The passing of the Indian Patents Act of 1970 encourages indigeneous pharma industry in India to ensure affordable drugs.
Inauguration of the CIPLA Research and Production Complex by Mrs. Luba K. Hamied. (Oct 22, 1977)
Installation of an ORG 2001 computer at Mumbai Central Headquarters to ease the process of financial accounts and pay rolls, saving 20 days labour of seven persons.
The Chemical, Industrial and Pharmaceutical Laboratories Ltd.' is officially re-christened as 'Cipla Ltd'
Inauguration of Patalganga manufacturing plant
50 years of Cipla - Golden Jubilee celebrations
Cipla's receives its first USFDA approval for four bulk drugs, aiding exports to the US market
Cipla's turnover crosses Rs. 100 crores
Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families
Cipla proves its supremacy in the antiasthmatic segment by developing a range of CFC-free metered dose inhalers as well as the world’s first CFC-free budesonide inhaler. It is the first company outside the USA and Europe to launch CFC-free inhalers, a good 10 years before the deadline given by the Montreal Protocol
Dr. Y.K. Hamied delivers a historic speech at the European Commission in Brussels on HIV/AIDS, Malaria, Tuberculosis and Poverty Reduction
In a paradigm changing move, Cipla offers a triple AntiRetroViral cocktail to Médecins Sans Frontières (MSF) for $350/patient/year to battle HIV/AIDS
Dr. Y.K. Hamied wins the coveted Padma Bhushan Award by the late President of India, Dr. A. P. J. Abdul Kalam
Cipla's 75th Anniversary Celebrations
Cipla acquires 100% of share capital of Cipla Medpro (South Africa)
Strong Legacy, Stronger Future - Cipla's 80th Anniversary celebrations
Cipla shifts to professional management and announces its new Management Council
Acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. (USA)
Cipla Health Ltd. is established with a vision of becoming the most preferred consumer healthcare company in India
At the 21st International AIDS Conference in Durban, Cipla organises the 'Durban to Durban Forum' - a unique session wherein Dr. Y.K. Hamied delivered a speech marking Cipla's 16-year journey in fighting HIV/AIDS
Dr. Y.K. Hamied speaks about local manufacturing of ARVs in Africa and accelerating access to treatment at a United Nations meet in New York
Launch of Cipla SAGA (Sub-Saharan Africa and Global Access)
Cipla Palliative Care and Training Centre (CPC) marks its 20th anniversary, with a special program organised by the Cipla Patalganga team
Cipla launches Synchrobreathe, a state of the - art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
Cipla QCIL becomes the first privately founded Ugandan company and the first pharmaceutical company to be listed on the Uganda Securities Exchange.
Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
Cipla acquires novel anti-infective Elores to further anti- microbial stewardship in critical care in India.
Cipla offers strawberry flavored HIV drug, Quadrimune, for babies at a $1-a-day.
Cipla inaugurates it’s the office of its newly formed legal entity - Cipla (China) Pharmaceutical Co. Ltd, in Shanghai.
Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases.
Making further inroads into #Specialty & addressing unmet needs in the respiratory segment, our subsidiary, Cipla Technologies LLC (Cip Tec) partners with Pulmatrix for novel inhaled therapeutics for the treatment of ABPA in patients with Asthma.
Cipla USA furthers AMR stewardship with acquisition of key anti-infective ZEMDRI™
Alvotech and Cipla Gulf enter into a partnership for the Commercialization of key biosimilar in select emerging markets.
In continuance of its efforts to advance quality education and promote industry-academia collaboration, Cipla Foundation, funds the set-up of a world class chemistry research laboratory at the Indian Institute of Science Education and Research (IISER) Pune.
Cipla receives Great Place To Work Certification once again.
Cipla receives final approval for generic version of Proventil® HFA Inhalation Aerosol (Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation)
Cipla Foundation supports the set up of Maharashtra's only dedicated pediatric isolation ward for COVID-19
Cipla - Breathe Free Lanka Pvt Ltd. receives Great Place To Work certification. Cipla is one of the top 3 pharma companies in Sri Lanka
Cipla Foundation reaches out to local communities affected by Cyclone Amphan in West Bengal, India by providing essential hygeine and food supplies to those in need.
In June 2020, Cipla Foundation South Africa together with Miltons Matsemela hosted a virtual Youth Day Run to raise funds for frontline COVID healthcare workers.
Cipla signs a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India
Cipla launches remdesivir under its brand name CIPREMI. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.
Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs - Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin)
Cipla is granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in India under the brand name Ciplenza. Favipiravir is an off patent, oral anti-viral drug that has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.
Cipla completes 85 years on 17th August 2020.
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI).